Upper Urinary Tract Causes of Hematuria

Published on 22/03/2015 by admin

Filed under Pediatrics

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 993 times

Chapter 513 Upper Urinary Tract Causes of Hematuria

513.6 Vascular Abnormalities

Hemangiomas, hemangiolymphangiomas, angiomyomas, and arteriovenous malformations of the kidneys and lower urinary tract are rare causes of hematuria. They can manifest with microscopic hematuria or gross hematuria with clots. Cutaneous vascular malformations, when present, can offer a clue to these underlying causes of hematuria. Renal colic can develop if the upper tract is involved. The diagnosis may be confirmed by angiography or endoscopy.

Unilateral bleeding of varicose veins of the left ureter, resulting from compression of the left renal vein between the aorta and superior mesenteric artery (mesoaortic compression), is referred to as the nutcracker syndrome. Patients with this syndrome typically present with persistent microscopic hematuria (occasionally, recurrent gross hematuria) that may be accompanied by proteinuria, lower abdominal pain, flank pain, or orthostatic hypotension. Diagnosis is confirmed by Doppler ultrasonography, CT, phlebography of the left renal vein, or magnetic resonance angiography.

513.7 Renal Vein Thrombosis

513.8 Idiopathic Hypercalciuria

Idiopathic hypercalciuria, which may be inherited as an autosomal dominant disorder, can manifest as recurrent gross hematuria, persistent microscopic hematuria, dysuria, or abdominal pain in the absence of stone formation. Hypercalciuria can also accompany conditions resulting in hypercalcemia, such as hyperparathyroidism, vitamin D intoxication, immobilization, and sarcoidosis. Hypercalciuria may be associated with Cushing syndrome, corticosteroid therapy, tubular dysfunction secondary to Fanconi syndrome (Wilson disease, oculocerebrorenal syndrome), Williams syndrome, distal renal tubular acidosis, or Bartter syndrome. Hypercalciuria may also be seen in patients with Dent disease, which is an X-linked form of nephrolithiasis associated with hypophosphatemic rickets. Although microcrystal formation and consequent tissue irritation are believed to mediate symptoms, the precise mechanism by which hypercalciuria causes hematuria or dysuria is unknown.

Treatment

Left untreated, hypercalciuria leads to nephrolithiasis in approximately 15% of cases. Idiopathic hypercalciuria has been identified as a risk factor in 40% of children with kidney stones, and low urinary citrate level has been associated as a risk factor in approximately 38% of this group. Oral thiazide diuretics can normalize urinary calcium excretion by stimulating calcium reabsorption in the proximal and distal tubule. Such therapy can lead to resolution of gross hematuria or dysuria and can prevent nephrolithiasis. The precise indications for thiazide treatment remain controversial.

In patients with persistent gross hematuria or dysuria, therapy is initiated with hydrochlorothiazide at a dose of 1-2 mg/kg/24 hr as a single morning dose. The dose is titrated upward until the 24-hr urinary calcium excretion is <4 mg/kg and clinical manifestations resolve. After 1 yr of treatment, hydrochlorothiazide is usually discontinued but may be resumed if gross hematuria, nephrolithiasis, or dysuria recurs. During hydrochlorothiazide therapy, the serum potassium level should be monitored periodically to avoid hypokalemia. Potassium citrate at a dose of 1 mEq/kg/24 hr may also be beneficial, particularly in patients with low urinary citrate excretion and symptomatic dysuria.

Sodium restriction is important because calcium excretion parallels sodium excretion. Importantly, dietary calcium restriction is not recommended (except in children with massive calcium intake >250% of RDA by dietary history) because calcium is a critical requirement for growth and no evidence supports a relationship between decreased calcium intake and decreased urinary calcium levels. Reduced bone mineral density with evidence of bone resorption has been described in patients with hypercalciuria. In such patients, dietary calcium restriction is particularly contraindicated. Small-scale studies seem to support a role for bisphosphonate therapy, which leads to a reduction in urinary calcium excretion and improvement in bone mineral density. Controlled studies are necessary to establish a clear role for such therapy.